Image

The Role of Cardiovascular Magnetic Resonance in Patients With Non-ST- Elevation- Myocardial Infarction

The Role of Cardiovascular Magnetic Resonance in Patients With Non-ST- Elevation- Myocardial Infarction

Non Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this prospective study is to evaluate the role of cardiovascular magnetic resonance (CMR) in patients with suspected non-ST elevation myocardial infarction (NSTEMI). The main endpoint is the reclassification rate, defined as the number of patients in whom the information provided by pre-angiography CMR affects the revascularization strategy or the final diagnosis.

Participants will undergo to CMR before invasive coronary angiography (ICA).

Description

All patients with NSTEMI eligible for the study undergo CMR prior to ICA. To avoid any delay in patients' treatment all examination will be analyzed by local trained staff at each center. All patients will thereafter undergo ICA and the standard of care (SOC) decision-making on revascularization strategy and diagnosis will be declared by the treating physician, which will be blinded to the participation of the patients in the study and about CMR results. The treating physician will also declare patient's next management according to ICA results. After having declared the diagnosis, the treating physician will then be informed about the CMR findings. Therefore, according to CMR results the treating physician may eventually modify the initial diagnosis and management. Treatment plan modifications include difference in the identification of the culprit lesion, referring the patient to medical therapy instead of a revascularization procedure or viceversa, switching from a percutaneous to a surgical revascularization procedure or viceversa, or need for further cardiac or non-cardiac investigations. Initial diagnosis includes confirmed NSTEMI or all other possible alternative diagnosis and proposed additional diagnostic examination(s) for further differential diagnosis.

The CMR-modified SOC (CMR-SOC) and diagnosis made considering CMR results will be collected.

Eligibility

Inclusion Criteria:

  • Age > 18 years old
  • Presence of criteria for acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction:
  • Signs and symptoms of myocardial ischemia
  • Detection of acute myocardial injury defined as a rise and/or fall of high-sensitivity cardiac Troponin (hs-cTn) values with at least one value above the 99th percentile Upper Reference Limit at baseline or after presentation.
  • Patients scheduled for ICA.
  • Written informed consent.

Exclusion Criteria:

  • Patients diagnosed with myocardial infarction with ST segment elevation.
  • Very High-risk NSTEMI patients according to 2020 ESC Guidelines on Acute Coronary
    Syndromes
  • Haemodynamic instability
  • Cardiogenic shock
  • Recurrent/refractory chest pain despite medical treatment
  • Life-threatening arrhythmias
  • Mechanical complications of MI
  • Acute heart failure clearly related to NSTEMI
  • ST-segment depression>1mm/6 leads plus ST-segment elevation aVR and/or V1.
  • Legally incompetent to provide informed consent
  • Participation in another clinical study.
  • Regular known contraindications to CMR at time of inclusion such as:
  • Severe renal impairment (eGFR < 30 ml / min / 1,73 m2) or on dialysis treatment
  • Claustrophobia
  • Known pregnancy or breast-feeding patients
  • Non MR compatible devices
  • Known allergy to Gadolinium

Study details
    Non-ST Elevation Myocardial Infarction (NSTEMI)

NCT05751057

Cardiocentro Ticino

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.